1. Home
  2. Analysis
  3. Cevimeline
  4. Tymlos

Cevimeline and Tymlos drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Cevimeline (cevimeline hydrochloride) and Tymlos (abaloparatide). Common drug interactions include fatigue among females.

The phase IV clinical study analyzes what interactions people have when they take Cevimeline and Tymlos. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.

What is Cevimeline?

Cevimeline has active ingredients of cevimeline hydrochloride. It is often used in sjogren syndrome. eHealthMe is studying from 1,480 Cevimeline users. Check the latest studies of Cevimeline.

What is Tymlos?

Tymlos has active ingredients of abaloparatide. eHealthMe is studying from 16,516 Tymlos users. Check the latest studies of Tymlos.

On Jul, 15, 2026

13 people who take Cevimeline and Tymlos together, and have interactions are studied.

Cevimeline and Tymlos drug interactions.

What are the common drug interactions of Cevimeline and Tymlos, by gender? *:

female:

  1. Fatigue (feeling of tiredness)
  2. Malaise (a feeling of general discomfort or uneasiness)
  3. Dizziness
  4. Eructation (release of gas from the digestive tract)
  5. Hypotension (abnormally low blood pressure)
  6. Injection site bruising
  7. Injection site discolouration
  8. Nasopharyngitis (inflammation of the nasopharynx)
  9. Nausea (feeling of having an urge to vomit)
  10. Neuralgia (pain in one or more nerves)

male:

n/a

What are the common drug interactions of Cevimeline and Tymlos, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Weight increased

50-59:

n/a

60+:

  1. Malaise (a feeling of general discomfort or uneasiness)
  2. Diarrhoea
  3. Tachycardia (a heart rate that exceeds the range of 100 beats/min)
  4. Dizziness
  5. Eructation (release of gas from the digestive tract)
  6. Fatigue (feeling of tiredness)
  7. Headache (pain in head)
  8. Hypotension (abnormally low blood pressure)
  9. Injection site pain
  10. Nausea (feeling of having an urge to vomit)

What are the existing conditions these people have? *

  1. Osteoporosis Post-Menopausal (weak bone with possibility to break after stopped menstrual cycles): 6 people, 46.15%
  2. Senile Osteoporosis (weak bones with ageing): 4 people, 30.77%
  3. Rheumatoid Factor Positive: 2 people, 15.38%
  4. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 15.38%
  5. Pathological Fracture (broken bone caused by disease): 2 people, 15.38%
  6. Osteoporosis (bones weak and more likely to break): 2 people, 15.38%
  7. Osteoporotic Fracture (fracture due to weak bone): 1 person, 7.69%
  8. Cough: 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Cevimeline and Tymlos?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Cevimeline and Tymlos:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Cevimeline:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Tymlos:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Cevimeline and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Tymlos and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on cevimeline hydrochloride and abaloparatide (the active ingredients of Cevimeline and Tymlos, respectively), and Cevimeline and Tymlos (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.